Form 4: Bristol-Myers Squibb Director Peter J. Arduini Acquires Additional Deferred Share Units

Bristol-Myers Squibb Director Peter J. Arduini acquired 729.099 Deferred Share Units, increasing his beneficial ownership to 62,988.874 units, as part of deferred compensation and reinvested dividends.

Summary

• Peter J. Arduini, a Director of Bristol-Myers Squibb Company (BMY), acquired 729.099 Deferred Share Units (DSUs) on June 30, 2025.
• Each Deferred Share Unit will convert into one share of common stock upon settlement.
• Settlement of the DSUs occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• Following this transaction, Peter J. Arduini beneficially owns a total of 62,988.874 Deferred Share Units.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• A Power of Attorney was executed on June 24, 2025, by Peter J. Arduini, authorizing specific individuals to handle his insider reporting requirements under Section 16 of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The acquisition of deferred share units by a director is a routine compensation event, indicating continued alignment of interests with shareholders through equity ownership, which is generally viewed as a positive or neutral signal.

Positives

• The acquisition of Deferred Share Units by a director aligns their interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The transaction represents a routine component of director compensation, indicating continued commitment and investment in the company by its leadership.

Future Outlook

Deferred Share Units held by the reporting person will become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person, converting into shares of common stock.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation. It reflects a common practice in the pharmaceutical and biopharmaceutical industry where non-employee directors receive equity-based awards as part of their compensation package to align their interests with long-term shareholder value.

Comparison to Industry Standards

• The acquisition of Deferred Share Units as part of director compensation is a common practice among large pharmaceutical and biopharmaceutical companies, aligning director interests with long-term shareholder value.
• This mechanism is consistent with corporate governance best practices observed in companies like Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK), where non-employee directors often receive a portion of their compensation in equity-based awards.

Corporate Governance

Related Party Transactions

• Acquisition of Deferred Share Units by Peter J. Arduini, a director of Bristol-Myers Squibb Company, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The acquisition of equity-based compensation by a director aligns their financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• Settlement of the Deferred Share Units into common stock upon Peter J. Arduini ceasing to be a director or at a future specified date.

Key Dates

Recommendation

Keywords

Bristol-Myers Squibb, BMY, Peter J. Arduini, Form 4, Insider Transaction, Deferred Share Units, Director Compensation, Pharmaceuticals, Biopharma, Equity Compensation